TransCode Therapeutics (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the retirement of Chief Financial Officer Tom Fitzgerald, who has served in the role since July 2018. Fitzgerald will resign as CFO and a director effective immediately while continuing to provide transition services. The company named John Tattory interim CFO, effective immediately.
Tattory brings more than 25 years of financial and operational management and leadership experience across pharmaceutical, medical device and biotechnology companies. His background includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics and Windtree Therapeutics. He currently serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies.
The leadership change comes at a critical time for TransCode Therapeutics as it advances its pipeline of novel cancer treatments. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a unique and well-documented biomarker of metastasis. Additionally, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
Fitzgerald’s retirement and Tattory’s appointment could signal a shift in financial strategy as the company navigates the complex landscape of clinical development. With Tattory’s extensive experience in life sciences and his current role providing consulting CFO services, he may bring a fresh perspective to TransCode’s financial operations. The transition services provided by Fitzgerald should help ensure continuity during the change.
Investors and stakeholders will be watching closely to see how the new interim CFO manages the company’s financial health, especially given the capital-intensive nature of oncology research and development. The success of TTX-MC138 and other candidates will depend not only on scientific breakthroughs but also on strategic financial management.
For more details, the full press release is available at https://nnw.fm/8G3ik. The latest news and updates relating to RNAZ can be found in the company’s newsroom at https://nnw.fm/RNAZ.
NetworkNewsWire, a specialized communications platform focused on financial news and content distribution, provides additional information at https://www.NetworkNewsWire.com. Full terms of use and disclaimers are available at https://www.NetworkNewsWire.com/Disclaimer.
